FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours ner response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Strei Katherine					2. Issuer Name and Ticker or Trading Symbol  Emergent BioSolutions Inc. [ EBS ]									eck all appli Direct	k all applicable) Director		10% Ov	vner	
`	/	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/24/2021									helow)	) ``	f HR	below)		
		20879 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	e) X Form t Form t	lividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
	Ta	ble I - No	n-Deri	vativ	e Se	curitie	s Ac	quired,	Dis	posed c	of, o	r Ben	eficial	y Owned	ł				
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)						Securiti Benefic Owned	5. Amount of Securities Beneficially Owned Following		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount		(A) or (D)	Price	Transac	Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock			02/2	24/2021				A		2,674(1)		A	\$0	30	30,655		D		
Common Stock			02/2	4/2021				A		2,674(2)		A	\$0	33	33,329		D		
Common Stock <sup>(3)</sup>			02/2	4/2021				F		619		D	\$93.4	9 32	32,710		D		
Common Stock <sup>(3)</sup>			02/2	2/26/2021				F		649		D	\$97.1	5 32	32,061		D		
Common Stock <sup>(3)</sup> 02/			02/2	6/202	1			F	F 561 D \$		\$97.1	5 31	31,500		D				
		Table II -												Owned					
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any	Date,	Transa Code (	iction Instr.	of Derivati Securiti Acquire (A) or Dispose of (D) (I	ive ies ed ed nstr.	Expiration Date (Month/Day/Year)			of Securities Underlying Derivative Sect (Instr. 3 and 4)  Amor		security 4) Amount or Number	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficia Owned Following Reported	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	(Fig. 1) (Fig. 2) (Fi	(First) DFESSIONAL DRIVE 1000 ERSBURG MD (State)  Ta Security (Instr. 3)  Stock Month/Day/Year)	(First) (Middle)  DFESSIONAL DRIVE  1000  ERSBURG MD 20879  (State) (Zip)  Table I - No  Security (Instr. 3)  Stock  Month/Day/Year)  Stock  A Deems Execution if any (Month/Day/Year)   Stock and stoc	(First) (Middle)  DFESSIONAL DRIVE  1000  ERSBURG MD 20879  (State) (Zip)  Table I - Non-Derive (Month)  Security (Instr. 3) 2. Translate (Month)  2 Stock 02/2  Stock 02/2  Table II - Derivate (e.g., 1)  2 Conversion or Exercise Price of Derivative (Month/Day/Year)  2 (Month/Day/Year)	(First) (Middle)  DFESSIONAL DRIVE  100  Table I - Non-Derivativ  Security (Instr. 3)  Table I - Non-Derivativ  (Month/Day/Yea  Stock  1 Stock  1 Stock  1 Stock  1 Stock  2 Table II - Derivative (e.g., puts, puts, if any (Month/Day/Year)  Conversion or Exercise Price of Derivative (Month/Day/Year)  2 Table II - Derivative (e.g., puts, if any (Month/Day/Year) (Month/Day/Year)  3 A. Deened Execution Date, if any (Month/Day/Year) (Month/Day/Year)  3 A. Deened Execution Date, if any (Month/Day/Year) (Month/Day/Year)	State   Conversion of Exercise   Price of Derivative Security (Instr. 3)   Conversion of Exercise   Conversion of Exerc	(First) (Middle)  (First) (Month/Day/Year)  (First) (Middle)  (First) (Middle)  (First) (Month/Day/Year)  (F	Emergent BioSo  (First) (Middle)  (First) (Month/Day/Year)  (Stock (Zip)  (First) (Month/Day/Year)  (First) (Middle)  (First) (Month/Day/Year)  (First) (Middle)  (First) (Middle)  (First) (Month/Day/Year)  (First) (Middle)  (First) (Month/Day/Year)  (First) (Middle)  (First) (Month/Day/Year)  (First) (Middle)  (First) (Month/Day/Year)  (A) Date of Earliest Trans (2/24/2021)  (A) Deemed Execution Date, if any (Month/Day/Year)  (First) (Month/Day/Year)  (First) (Middle)  (First) (Month/Day/Year)  (First) (Month/Day/Year)  (First) (Middle)  (First) (A) Date of Carliest Trans (2/24/2021)  (A) Deemed Execution Date, if any (Month/Day/Year)  (First) (Month/Day	Emergent BioSolutions    Conversion of Exercise of Derivative Securities Acquired, Described in Stock   Stock	Emergent BioSolutions Inc  (First) (Middle)  DESSIONAL DRIVE  1000  Table I - Non-Derivative Securities Acquired, Disposed of (D) (Instr. 3)  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3), 4 and 5)  Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 3), 4 and 5)  Emergent BioSolutions Inc  3. Date of Earliest Transaction (Month/Day/24/2021  4. If Amendment, Date of Original Filed  2. Transaction Date (Execution Date, if any (Month/Day/Year)  2. Transaction Date (Instr. 4)  3. Transaction Code (Instr. 4)  4. If Amendment, Date of Original Filed  2. Transaction Date (Month/Day/Year)  3. Transaction Code (Instr. 4)  4. If Amendment, Date of Original Filed  3. Transaction Date (Month/Day/Year)  4. If Amendment, Date of Original Filed  3. Transaction Date (Month/Day/Year)  4. If Amendment, Date of Original Filed  3. Transaction Code (Instr. 4)  4. If Amendment, Date of Original Filed  3. Deemed Execution Date, if any (Month/Day/Year)  4. If Amendment, Date of Original Filed  3. Transaction Code (Instr. 4)  4. If Amendment, Date of Original Filed  3. Transaction Date (Instr. 4)  4. If Amendment, Date of Original Filed  3. Transaction Code (Instr. 4)  4. If Amendment, Date of Original Filed  5. Date Exercise Expertise Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	ERSBURG MD 20879  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of (e.g., puts, calls, warrants, options, convertification of Exercision Derivative Securities Acquired (A) or Exercision of	Emergent BioSolutions Inc. [EBS]  3. Date of Earliest Transaction (Month/Day/Year) 02/24/2021  4. If Amendment, Date of Original Filed (Month/Day/Year) 02/24/2021  4. If Amendment, Date of Original Filed (Month/Day/Year) 02/24/2021  5. Table I - Non-Derivative Securities Acquired, Disposed of (Month/Day/Year) 02/24/2021  6. Stock 02/24/2021  7. Table II - Derivative Securities Acquired, Disposed of (Original Filed (Month/Day/Year) 02/24/2021  8. Stock 02/26/2021  9. Stock 02/26/2021  8. Stock 02/26/2021  9. Stock 03. Transaction 04. Stock 02/26/2021  9. Stock 04. Stock 05. Stock 06. Date Exercisable and 7. Transaction Code (instr. 8) 08. Stock 09. Stock	Emergent BioSolutions Inc. [EBS]  3. Date of Earliest Transaction (Month/Day/Year) 02/24/2021  4. If Amendment, Date of Original Filed (Month/Day/Year)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Benefic (Month/Day/Year) (Month/Day/Year) (A) or (D)	Emergent BioSolutions Inc. [EBS]  (Chatterine  (First) (Middle)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficial Security (Instr. 3)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year) (Month/Day/Year)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficial Security (Instr. 3)  2. Transaction (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year) (Month/Day/Year)  (Stock 02/24/2021	Emergent BioSolutions Inc. [EBS]    Check all applications   Confice   Confi	Emergent BioSolutions Inc. [EBS]    Check all applicables   Code (Instr. 3)	Emergent BioSolutions Inc. [EBS]  (Check all applicable) Diffector V Officer (give title below)  (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned Form fleed by More than Person  Table I - Non-Derivative Securities Acquired, Disposed of (n) in Price (log) (linstr. 3, and 4)  Security (Instr. 3)  Diffection Date, (Month/Day/Year) (Month/Day/Year)  Diffection Date, (Month/Day/Year) (Month/Day/Year) Diffection Date, (Month/Day/Year) Di	Emergent BioSolutions Inc.   EBS	

## **Explanation of Responses:**

\$93,49

1. Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

(4)

- 2. Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
- 3. Represents shares of common stock withheld to pay taxes.

02/24/2021

4. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

## Remarks:

Employee Stock

**Options** 

(Right to Buy)

> /s/ S. Scott Lieberman, Attorney-in-fact

\*\* Signature of Reporting Person

10,696

\$93,49

02/23/2028

Common

Stock

02/26/2021

Date

10.696

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Α

(A)

10.696

(D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.